Home > Insider Trading > Filing (0001140361-10-024996)

Filing Details

Accession Number:: 0001140361-10-024996
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-06-10 13:00:00
Reporting Period:: 2010-05-26

Filing Date:: 2010-06-10
Accepted Time:: 2010-06-10 11:54:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885317	Ophthalmic Imaging Systems	OISI	Surgical & Medical Instruments & Apparatus (3841)	943035367

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1321178	Moshe Arkin	6 Hachoshlim St Herzelia L3	Yes	No	Yes	No
1467668	Ltd. (2009) Management Accelmed A.m.	6 Hachoshlim St Herzelia L3	Yes	No	Yes	No
1467669	Ltd. (1999) Arkin M.	6 Hachoshlim St Herzelia L3	Yes	No	Yes	No
1467670	U.m. Accelmed, Limited Partnership	6 Hachoshlim St Herzelia L3 L3	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-05-26	3,581,089	$0.00	13,338,603	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock	Acquisiton	2010-05-26	1,193,696	$0.00	1,193,696	$1.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,193,696		2012-06-23	No	4	P	Direct

Footnotes

On May 26, 2010, Ophthalmic Imaging Systems, a California corporation (the "Company"), issued and sold to U.M. AccelMed, Limited Partnership, an Israeli limited partnership ("AccelMed"), 3,581,089 shares of the Company's common stock, no par value, and a warrant to purchase up to 1,193,696 shares of common stock, for an aggregate purchase price of $1,999,967.
These securities are owned directly by AccelMed and indirectly by A.M. AccelMed Management (2009) Ltd., the general partner of AccelMed (the "General Partner"), M. Arkin (1999) Ltd ("M. Arkin (1999)"), the beneficial owner of 80% of the outstanding shares of the General Partner, and Moshe Arkin, the sole director and the beneficial owner of 99.9% of the outstanding shares of M. Arkin (1999).
The filing of this Form 4 shall not be construed as an admission that the General Partner, M. Arkin (1999) or Mr. Arkin is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, the beneficial owner of any of the shares of common stock of the Company owned by AccelMed. Pursuant to Rule 16a-1, each of the General Partner, M. Arkin (1999) and Mr. Arkin disclaim beneficial ownership of the shares of the Company reported herein that are beneficially owned by AccelMed, except to the extent of their pecuniary interest therein.
This warrant may be exercised beginning on the earliest of the following: (i) the date that the Company consummates a merger with and into another corporation or the date the Company consummates a sale, transfer or other disposition of all or substantially all of its assets, (ii) the date that the average closing price per share of the Company's common stock on the OTC Bulletin Board (or wherever the Company's common stock is listed or quoted for trading on the date in question) for 10 consecutive trading days exceeds $2.00, (iii) the date the Company's Board of Directors offers a transaction pursuant to which the Company will raise at least $1.5 million in a capital raising transaction with persons who are shareholders of MediVision Medical Imaging Ltd. (a large shareholder of the Company), and (iv) March 23, 2012.